Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States.

Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarró M, Kaye JA.

Prostate Cancer. 2019 Feb 11;2019:4387415. doi: 10.1155/2019/4387415. eCollection 2019.

2.

The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.

Krasnow RE, Rodríguez D, Nagle RT, Mossanen M, Kibel AS, Chang SL.

Urol Oncol. 2018 Nov;36(11):500.e11-500.e19. doi: 10.1016/j.urolonc.2018.06.007. Epub 2018 Sep 21.

PMID:
30249519
3.

Second primary malignancy after radical prostatectomy in a cohort from the Middle East.

Shahait M, Mukherji D, Hamieh N, Nassif S, Jabbour M, Khauli R, Bulbul M, Abou Kheir W, El Hajj A.

Prostate Int. 2018 Jun;6(2):46-49. doi: 10.1016/j.prnil.2017.09.002. Epub 2017 Sep 30.

4.

Italian cancer figures, report 2013: Multiple tumours.

AIRTUM Working Group.

Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152. English, Italian.

5.

A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.

Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):127-35. doi: 10.1016/j.ijrobp.2009.07.1692. Epub 2009 Nov 10.

PMID:
19910129
6.

Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study.

Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA.

Cancer. 2014 Sep 1;120(17):2735-41. doi: 10.1002/cncr.28769. Epub 2014 May 19.

7.

Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.

Hernandez RK, Cetin K, Pirolli M, Quigley J, Quach D, Smith P, Stryker S, Liede A.

Can J Urol. 2015 Aug;22(4):7858-64.

PMID:
26267023
8.

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.

Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikström P.

Eur Urol. 2017 May;71(5):776-787. doi: 10.1016/j.eururo.2016.07.033. Epub 2016 Aug 3.

9.

Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database.

Hirst CJ, Cabrera C, Kirby M.

Cancer Epidemiol. 2012 Dec;36(6):e349-53. doi: 10.1016/j.canep.2012.07.012. Epub 2012 Aug 19.

PMID:
22910034
10.

Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.

Shah BK, Khanal A.

Anticancer Res. 2015 Jun;35(6):3437-40.

PMID:
26026107
11.

Second Primary Malignancies in Adults with Gastric Cancer - A US Population-Based Study.

Shah BK, Khanal A, Hewett Y.

Front Oncol. 2016 Apr 11;6:82. doi: 10.3389/fonc.2016.00082. eCollection 2016.

12.

Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.

Khanal A, Budhathoki N, Singh VP, Shah BK.

Anticancer Res. 2017 Apr;37(4):2033-2036.

PMID:
28373478
13.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Cancer. 2013 Aug 15;119(16):2990-8. doi: 10.1002/cncr.28102. Epub 2013 May 29.

14.

Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.

Jarosek SL, Virnig BA, Chu H, Elliott SP.

Eur Urol. 2015 Feb;67(2):273-80. doi: 10.1016/j.eururo.2014.08.061. Epub 2014 Sep 10.

PMID:
25217421
15.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
16.

The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.

Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES.

Eur Urol. 2014 Oct;66(4):646-52. doi: 10.1016/j.eururo.2014.01.018. Epub 2014 Jan 24.

17.

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D, Olmos D, Ferraldeschi R, Maier G, Thompson E, Parker C, Attard G, de Bono J.

Eur Urol. 2013 Aug;64(2):300-6. doi: 10.1016/j.eururo.2012.12.029. Epub 2013 Jan 4.

PMID:
23313031
18.

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.

Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I.

Cancer. 2011 Oct 1;117(19):4439-46. doi: 10.1002/cncr.26070. Epub 2011 Mar 22.

19.

Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study.

Pawlish KS, Schottenfeld D, Severson R, Montie JE.

Prostate. 1997 Oct 1;33(2):75-86.

PMID:
9316648
20.

Cancer incidence after localized therapy for prostate cancer.

Moon K, Stukenborg GJ, Keim J, Theodorescu D.

Cancer. 2006 Sep 1;107(5):991-8.

Supplemental Content

Support Center